An international research team led by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects. Their new material could be developed into an antimicrobial drug to treat patients with antibioticresistant infections.
This finding was reported in the scientific journal Nature Communications.
Superbugs that are resistant to antibiotics are a serious health threat. According to the UK Review on Antimicrobial Resistance, superbugs kill around 700,000 people worldwide each year. By 2050, 10 million people could die each year if existing antibiotics continue to lose their effectiveness.
“There is an urgent global need for new antimicrobials that are effective against superbugs. The situation has become more acute because bacteria are starting to develop resistance to the last-line antibiotics, which are given only to patients infected with bacteria resistant to available antibiotics,” said Professor Jackie Y. Ying, Executive Director of IBN.
The research community is trying to develop alternatives to antibiotics using synthetic polymers. However, the antimicrobial polymers developed so far are either too toxic for clinical use, not biodegradable or can only target one type of bacteria.
To address this problem, Dr Yi Yan Yang from IBN brought together a multidisciplinary research team from the US, China and Singapore to develop a new class of antimicrobial polymers called guanidinium-functionalized polycarbonates with a unique killing mechanism that can target a broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic to human cells.
The polymer kills bacteria in the following way. First, the polymer binds specifically to the bacterial cell. Then, the polymer is transported across the bacterial cell membrane into the cytoplasm, where it causes precipitation of the cell contents (proteins and genes), resulting in cell death.
The team tested the polymers on mice infected with five hard-to-treat multidrug-resistant bacteria: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, methicillinresistant Staphylococcus aureu and Pseudomonas aeruginosa. These superbugs are commonly acquired by patients in the hospitals and can cause systemic infections that lead to septic shock and multiple organ failure. The results showed that the bacteria were effectively removed from the mice and no toxicity was observed.
The researchers then further tested the effectiveness of the polymers on mice with two types of systemic infections caused by superbugs: peritonitis (an infection of the stomach’s inner lining) and lung infections from Pseudomonas aeruginosa. The polymers eliminated the bacterial infections in both groups of mice with negligible toxicity.
Dr Yi Yan Yang, Group Leader at IBN said, “We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity. Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections.”
“This study illustrates the potential for this new research field we denote as ‘macromolecular therapeutics’ to create entirely new classes of treatments for multiple diseases,” said Dr James Hedrick, Distinguished Research Staff Member, IBM Research – Almaden, San Jose, California. “In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases. The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance.”
To determine whether the bacteria will develop any resistance to the polymer, the team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research – Almaden to perform genomic analysis. They found that the bacteria did not show any resistance development even after multiple treatments with the polymer.
The Latest on: Antimicrobial drug
- 2017 Antimicrobial Animal Drug Report on December 18, 2018 at 9:46 pm
Washington, DC - Every year, at least two million Americans are sickened by serious infections caused by antimicrobial-resistant (AMR) pathogens, such as MRSA. And, at least 23,000 people die as a dir... […]
- Alzheimer's drug may help battle antibiotic resistance on December 18, 2018 at 1:33 pm
Dangerous antibiotic-resistant bacteria could soon be targeted with a drug initially developed to treat Alzheimer's disease. University of Queensland-led research investigated the antibacterial ... […]
- Push to Tighten Antibiotic Use on December 18, 2018 at 1:22 pm
The framework for antibiotic use comes out as the FDA released its 2017 report on antimicrobial drugs sold for use in livestock. The report states there was a 33% decline from 2016 to 2017 in the sale... […]
- FDA: Livestock antibiotic usage falls by one-third on December 18, 2018 at 10:00 am
“The sales trends reflected by the 2017 report are very encouraging, and I’m pleased to see that the sales and distribution of these antimicrobial drugs has declined significantly the past two years,” ... […]
- FDA reports trends in antibiotic sales, distribution on December 18, 2018 at 10:00 am
“The data summarized in the 2017 Sales/Distribution report is collated from estimates of antimicrobial animal drug product sales for that year provided by the drug manufacturers and can’t be substitut... […]
- McDonald’s announces plan to cut antibiotic use on December 12, 2018 at 8:59 am
Overuse of antibiotics in both humans and animals has been fueling antibiotic resistance and contributing to growing problems with drug-resistant "superbugs" that can't be easily treated, according to ... […]
- McDonald's to curb antibiotic use in its beef supply on December 11, 2018 at 8:53 pm
The Food and Drug Administration last year said sales and distribution ... in 2018 from producers that have pledged to reduce by 20 percent their use of an antibiotic. “What McDonald’s is doing will h... […]
- Stop sterilizing your dust—Antimicrobial chemical tied to antibiotic resistance genes in dust on December 11, 2018 at 10:08 am
"They code for resistance to medically relevant antibiotic drugs." Up until 2017, manufacturers commonly added triclosan to antibacterial hand soaps and cleaning solutions. The Federal Drug ... […]
- Researchers remake wasp toxin into antibiotic drugs on December 10, 2018 at 2:57 pm
Researchers from the Massachusetts Institute of Technology (MIT) have transformed toxin in wasps into potential antibiotic drugs that may cure hard to cure bacterial infections. [Courtesy] US. Researc... […]
- MIT Engineers Repurpose Wasp Venom as an Antibiotic Drug on December 10, 2018 at 7:47 am
The venom of insects such as wasps and bees is full of compounds that can kill bacteria. Unfortunately, many of these compounds are also toxic for humans, making it impossible to use them as antibioti... […]
via Google News and Bing News